2m 2m 2m 2m 2m 2m 2m
Cytodyn (CYDY)
OTC
$0.28-$0.01 (-3.75%)
Price as of Jun 03, 2026- $415.0MMarket Cap
- -19.60%1-Year Change
- BiotechnologyIndustry
Cytodyn (CYDY)
$0.28-$0.01 (-3.75%)
Annual
Quarterly
05/31/2025 | 05/31/2024 | 05/31/2023 | 05/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 0 -100.00% | 266,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | 53,000 0.00% | 53,000 N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 213,000 0.00% | 213,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | N/A N/A | -7.2M +175.08% | -2.6M -90.27% | -27.0M -53.72% | |
Depreciation and Amortization Expense | 18,000 -37.93% | 29,000 -83.43% | 175,000 -77.59% | 781,000 -56.54% | |
Total Operating Expenses | -9.7M -153.50% | 18.1M -55.50% | 40.6M -72.14% | 145.6M +39.22% | |
Operating Profit | 9.7M +153.50% | -18.1M -55.50% | -40.6M -72.09% | -145.4M +39.01% | |
Interest Income | 565,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 565,000 N/A | 0 N/A | 0 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Income before Taxes | 3.7M +107.51% | -49.8M -37.56% | -79.8M -62.14% | -210.8M +36.30% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | 407,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 3.7M +107.51% | -49.8M -37.56% | -79.8M -62.14% | -210.8M +36.30% | |
Net Income from Continuing Operations Applicable to Common | 3.7M +107.51% | -49.8M -37.56% | -79.8M -62.14% | -210.8M +36.30% | |
Basic EPS and Net Income | 0.00 +100.00% | -0.05 -50.00% | -0.10 -67.74% | -0.31 N/A | |
Diluted EPS and Net Income | 0.00 +100.00% | -0.05 -50.00% | -0.10 -67.74% | -0.31 +14.81% | |
Basic Weighted Average Shares | 1.2B +24.37% | 969.5M +15.90% | 836.5M +23.58% | 676.9M +15.20% | |
Diluted Weighted Average Shares | 1.2B +28.20% | 969.5M +15.90% | 836.5M +23.58% | 676.9M +15.20% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 11.9M +282.73% | 3.1M +22.39% | 2.5M -39.94% | 4.2M -87.53% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 11.9M +282.73% | 3.1M +22.39% | 2.5M -39.94% | 4.2M -87.53% | |
Total Current Assets | 17.9M +65.31% | 10.8M +0.09% | 10.8M +2.76% | 10.5M -91.89% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | 73,000 -45.52% | |
Total Long-Term Assets | 169,000 -47.35% | 321,000 -34.09% | 487,000 +567.12% | 73,000 -45.52% | |
Total Assets | 18.0M +62.06% | 11.1M -1.38% | 11.3M -61.31% | 29.2M -77.90% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 27.2M -8.70% | 29.8M -13.44% | 34.4M -5.03% | 36.2M -46.66% | |
Total Current Liabilities | 70.5M -16.23% | 84.2M -29.73% | 119.8M -2.73% | 123.2M -19.26% | |
Total Long-Term Debt | 16.4M +2,199.44% | 714,000 0.00% | 714,000 -99.15% | 84.4M +901.42% | |
Total Long-Term Liabilities | 43.6M 0.00% | 43.6M +15,296.11% | 283,000 -32.94% | 422,000 -23.55% | |
Total Liabilities | 114.1M -10.79% | 127.9M +5.88% | 120.8M -2.26% | 123.6M -19.28% | |
Retained Earnings | -887.8M -0.42% | -891.5M +5.92% | -841.7M +9.86% | -766.1M +49.84% | |
Total Stockholders Equity | -96.0M -17.74% | -116.8M +6.63% | -109.5M +16.00% | -94.4M +349.13% | |
Total Shares Outstanding | 1.2B +18.01% | 1.1B +15.23% | 918.6M +27.66% | 719.6M +15.01% | |
Cash Flow | |||||
Cash from Operating Activities | -8.8M -20.19% | -11.0M -56.26% | -25.1M -67.69% | -77.7M -33.89% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | 122,000 0.00% | |
Cash from Investing Activities | N/A N/A | N/A N/A | N/A N/A | -122,000 0.00% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 10.9M -7.61% | 11.7M -60.74% | 29.9M -37.67% | 48.0M -65.04% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | 80.08% N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | -54,663.16% N/A | |
Return on Assets | 25.67% +105.77% | -444.45% +12.69% | -394.42% +50.85% | -261.46% +54.33% | |
Return on Equity | -3.52% -107.99% | 44.06% -43.73% | 78.30% -78.57% | 365.32% -72.25% | |
Revenue Growth | N/A N/A | N/A N/A | -100.00% N/A | N/A N/A | |
Current Ratio | 0.25 +97.28% | 0.13 +42.46% | 0.09 +5.62% | 0.09 -89.95% | |
Cash Ratio | 0.17 +357.45% | 0.04 +74.06% | 0.02 -38.37% | 0.03 -84.54% | |
Debt-to-Equity Ratio | -0.45 +73.82% | -0.26 -18.55% | -0.32 -74.90% | -1.28 -64.82% | |
Debt-to-Assets Ratio | 2.42 -11.78% | 2.74 -11.94% | 3.11 -24.76% | 4.13 +614.97% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow